Oral Presentation Joint Scientific Meeting of the Australian & NZ Head & Neck Cancer Society & NZ Association of Plastic Surgeons

Therapeutic potential for the treatment of adenoid cystic carcinoma (1386)

James Nightingale 1 2 , Benedict Lum 2 , Rahul Ladwa 1 , Fiona Simpson 2 , Benedict Panizza 1
  1. Princess Alexandra Hospital, Brisbane Australia, Woolloongabba, QLD, Australia
  2. The University of Queensland , Diamantina Institute, QLD, Australia


The natural history of adenoid cystic carcinoma (ACC) is relentless, defined by treatment failure, locoregional recurrence and metastatic disease. Treatment options are limited to palliative systemic therapy. Despite the introduction of therapies against new treatment targets, clinical trials present poor response rates and survival benefit.



Our research is focused on improving the therapeutic potential for treatment targets in head and neck ACC. This work has focused on the application of novel prochlorperazine (PCZ) combination therapy to promote increased clustering of treatment targets. This repurposing of PCZ is centred on inhibition of dynamin mediated endocytosis pathways. The combination therapy of PCZ and cetuximab (anti-EGFR) combination therapy has recently completed phase I clinical trials and is soon to commence phase II trial. Our research is now centred on the application of PCZ combination therapy to ACC treatment targets, including prostate specific membrane antigen (PSMA). PSMA is expressed in up to 94% of ACC cases and is internalised via the same mechanisms as EGFR opening the possibility of PCZ combination therapy to promote tumour homogeneity and improved treatment responses.



We present application of PSMA from its namesake in the prostate to head and neck ACC. This includes PCZ spatiotemporal manipulation across preclinical models in PSMA expressing disease. This translational research is centred on improved PET staging, radionuclide and immunotherapy applications. This is underpinned by presented clinicopathological data and correlated treatment targets highlighting an ACC patient population in need for improved treatment.



This presentation presents the foundation for improving response rates and outcomes for therapeutics undergoing clinical trial and future immunotherapy applications in ACC and PSMA expressing cancers.